CTIS2022-502952-30-00招募中1 期
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic functioActivated Phosphoinositide 3-Kinase Delta SyndromeMedDRA version: 20.0Level: PTClassification code: 10078281Term: Activated PI3 kinase delta syndrome Class: 100000004850CTIS2023-508519-22-00Pharming Technologies B.V.32
已完成
不适用
An open-label, parallel-group, single-dose study to evaluate the absolute bioavailability and tolerability of subcutaneous UCB4940 in healthy subjectsrheumatoid arthritisNL-OMON41792CB Celltech30
进行中（未招募）
不适用
Study to investigate the effect of liver impairment on the way the body eliminates the drug BAF312 in patients with mild, moderate and severe liver impairment compared to healthy persons.subjects with mild (Group 1), moderate (Group 2), and severe (Group 3) hepatic impairment.EUCTR2012-000562-37-HUovartis Pharma Services AG48
进行中（未招募）
1 期
A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in Children with Asthma (6 to Less Than 12 Years of Age)AsthmaEUCTR2017-002060-40-Outside-EU/EEATeva Branded Pharmaceutical Products R&D, Inc.36
进行中（未招募）
不适用
A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjectsMild and moderate hepatic impairmentMedDRA version: 14.1Level: PTClassification code 10024670Term: Liver disorderSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2012-000983-27-DEovartis Pharma Services AG32